OneSource Specialty Pharma Limited has made significant strides in the contract development and manufacturing organization (CDMO) sector. The company announced that its partner, Orbicular Pharmaceutical Technologies, has received tentative approval from the U.S. Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) concerning a generic formulation of Ozempic (semaglutide injection).
Strategic Partnership and Development
OneSource has played a pivotal role in this achievement, acting as the CDMO partner and providing comprehensive manufacturing support for the U.S. market application. This collaboration emphasizes a seamless development-to-submission model, showcasing the synergy between Orbicular’s product development leadership and OneSource’s manufacturing expertise.
Orbicular spearheaded the technical program for the complex peptide involved in the generic formulation. Meanwhile, OneSource contributed its manufacturing capabilities to facilitate the regulatory submission and ensure a future supply stream for commercialization.
Commitment to Manufacturing Excellence
The company plans to commence commercial manufacturing from its flagship facility in Bengaluru, which is already approved by the FDA. This strategic location is designed to ensure a consistent and reliable supply of the generic Ozempic to meet the demands of the U.S. market.
Neeraj Sharma, the CEO and Managing Director of OneSource Specialty Pharma Limited, expressed enthusiasm over this milestone. He stated that the tentative approval not only highlights Orbicular’s scientific prowess but also reinforces OneSource’s capabilities as a CDMO, particularly with its FDA-approved manufacturing site.
Growing CDMO Presence
This collaboration signifies the expanding role of OneSource as a global partner in the CDMO landscape, particularly in the realms of drug-device combinations, complex injectables, and specialty pharmaceutical products. Strategic alliances, like the one with Orbicular, are central to this growth trajectory.
OneSource specializes in complex product segments, including biologics and sterile injectables, and operates several manufacturing facilities recognized by global regulatory authorities. This enables them to deliver integrated development and manufacturing solutions to their international pharmaceutical clients.
Orbicular’s Expertise
Orbicular Pharmaceutical Technologies is a business-to-business (B2B) specialty pharmaceutical company focused on developing complex generics and specialty products. Their capabilities range from analytical characterization and regulatory strategy to technology transfer, making them a formidable player in the pharmaceutical landscape.
The tentative FDA approval signifies that the ANDA has met essential regulatory requirements, although it remains subject to final approval, which is often contingent upon patent or exclusivity issues.
Conclusion
The partnership between OneSource and Orbicular represents a significant advancement in the pharmaceutical industry, particularly in the development of complex generics. As the landscape continues to evolve, such collaborations will be crucial in addressing market needs and ensuring access to vital medications. The future looks promising for both companies as they navigate the intricacies of drug development and manufacturing.
- Key Takeaways:
- OneSource has strengthened its CDMO position through a partnership with Orbicular.
- The FDA’s tentative approval for a generic Ozempic marks a milestone in the collaboration.
- OneSource’s manufacturing capabilities are vital for meeting U.S. market demands.
- The partnership illustrates the importance of strategic alliances in the pharmaceutical sector.
- Both companies are poised for growth in the competitive landscape of specialty pharmaceuticals.
Read more → medicaldialogues.in